Goldman Sachs Raises Pfizer Price Target to $28 From $26
Goldman Sachs adjusted its Pfizer price target to $28 from $26 as part of its updated valuation analysis.
Goldman Sachs adjusted its Pfizer price target to $28 from $26 as part of its updated valuation analysis.